Literature DB >> 17542770

Pharmacogenetics of beta-blockers.

Jaekyu Shin1, Julie A Johnson.   

Abstract

Beta-blockers are an important cardiovascular drug class, recommended as first-line treatment of numerous diseases such as heart failure, hypertension, and angina, as well as treatment after myocardial infarction. However, responses to a beta-blocker are variable among patients. Results of numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to beta-blockers. This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17542770      PMCID： PMC2735790          DOI： 10.1592/phco.27.6.874

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  57 in total

Review 1.  Heart failure.

Authors:  Mariell Jessup; Susan Brozena
Journal:  N Engl J Med       Date:  2003-05-15       Impact factor: 91.245

2.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.

Authors:  Henrike Wuttke; Thomas Rau; Roland Heide; Klaus Bergmann; Michael Böhm; Joachim Weil; Dierk Werner; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2002-10       Impact factor: 6.875

3.  A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.

Authors:  G G Sofowora; V Dishy; M Muszkat; H G Xie; R B Kim; P A Harris; H C Prasad; D W Byrne; U B Nair; A J J Wood; C M Stein
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

4.  Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.

Authors:  David M Kaye; Belinda Smirk; Carolyn Williams; Garry Jennings; Murray Esler; Dianne Holst
Journal:  Pharmacogenetics       Date:  2003-07

5.  Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.

Authors:  Julie A Johnson; Issam Zineh; Brian J Puckett; Susan P McGorray; Hossein N Yarandi; Daniel F Pauly
Journal:  Clin Pharmacol Ther       Date:  2003-07       Impact factor: 6.875

6.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).

Authors:  Raymond J Gibbons; Jonathan Abrams; Kanu Chatterjee; Jennifer Daley; Prakash C Deedwania; John S Douglas; T Bruce Ferguson; Stephan D Fihn; Theodore D Fraker; Julius M Gardin; Robert A O'Rourke; Richard C Pasternak; Sankey V Williams
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

7.  Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.

Authors:  Jeanne Mialet Perez; Deborah A Rathz; Natalia N Petrashevskaya; Harvey S Hahn; Lynne E Wagoner; Arnold Schwartz; Gerald W Dorn; Stephen B Liggett
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

8.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure.

Authors:  Jeptha P Curtis; Seth I Sokol; Yongfei Wang; Saif S Rathore; Dennis T Ko; Farid Jadbabaie; Edward L Portnay; Stephen J Marshalko; Martha J Radford; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.

Authors:  Hazel L White; Rudolf A de Boer; Azhar Maqbool; Darren Greenwood; Dirk J van Veldhuisen; Richard Cuthbert; Stephen G Ball; Alistair S Hall; Anthony J Balmforth
Journal:  Eur J Heart Fail       Date:  2003-08       Impact factor: 15.534
View more
  38 in total

Review 1.  Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.

Authors:  J A Johnson; S B Liggett
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

2.  Pharmacogenomics and the failing heart are we waiting for godot?

Authors:  Douglas L Mann; Dennis M McNamara
Journal:  J Am Coll Cardiol       Date:  2008-06-23       Impact factor: 24.094

Review 3.  [Pharmacogenetics. Clinical relevance in anesthsiology].

Authors:  E M Zeidler; A E Goetz; C Zöllner
Journal:  Anaesthesist       Date:  2013-11       Impact factor: 1.041

4.  Pharmacogenomics of antihypertensive drugs: past, present and future.

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 5.  Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

Authors:  Julie A Johnson
Journal:  Circulation       Date:  2008-09-23       Impact factor: 29.690

Review 6.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

Review 7.  Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

Review 8.  Cardiovascular drugs and the genetic response.

Authors:  Sonny Dandona
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar

Review 9.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 10.  Practical Pharmacogenomic Approaches to Heart Failure Therapeutics.

Authors:  Chayakrit Krittanawong; Amalia Namath; David E Lanfear; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.